相关实验视频

Updated: Sep 10, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

对复发性或耐火性霍奇金淋巴瘤的ESHAP与IEV化疗

Mehdi Dehghani¹, Reza Vojdani¹, Abolfazl Khalafi-Nezhad²

¹Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

International journal of hematology-oncology and stem cell research

|August 25, 2025

概括

与埃托波西德,甲基普雷迪尼索隆,细胞氨基酸和 (ESHAP) 相比,ifosfamide,epirubicin,etoposide (IEV) 疗法在复发性或耐火性霍奇金病患者中显示出更高的疗效和更低的死亡率.

科学领域:

血液学
癌症学
药理学

背景情况:

高剂量化疗与自身干细胞移植 (ASCT) 是针对复发性/耐药性霍奇金淋巴瘤 (HL) 和非霍奇金淋巴瘤 (NHL) 的标准.
最佳的救援化疗方案尚不清楚,反应率,毒性,成本和干细胞损伤各不相同.
这项研究比较了两种救援方案:ESHAP (乙胺,甲胺,细胞氨基酸,) 和IEV (ifosfamide,epirubicin,乙胺).

研究的目的:

将ESHAP与IEV作为救援化疗的疗效和结果进行比较.
评估这些治疗方案在复发性或耐药性HL和NHL患者中的有效性.
确定这些血液恶性瘤的最佳救援治疗方法.

主要方法:

对276名复发性/ 耐药性HL和NHL患者的回顾性分析.
患者接受ESHAP或IEV作为救援化疗.
整体反应率 (ORR),完整反应率 (CR) 和死亡率的比较.

主要成果:

对于HL,IEV的ORR为85.6% (55.1%CR),而ESHAP的ORR为79.8% (50%CR).
对于NHL (使用Rituximab),IEV的ORR为72. 4% (42. 4%CR),而ESHAP的ORR为60. 9% (40. 3%CR) (P=0. 03).
与ESHAP相比,IEV治疗与较低的死亡率有关.

结论:

在治疗复发性或耐药性霍奇金淋巴瘤和非霍奇金淋巴瘤方面,IEV化疗方案优于ESHAP.
在该患者群体中,IEV 显示出更好的疗效和安全性.
应将IEV视为首选的救援处理选项.

关键词:

其他霍奇金淋巴瘤和非霍奇金淋巴瘤一个IEV

更多相关视频

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...